LIA
CRSP icon

Lynx Investment Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Lynx Investment Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125
Closed -$6.75K – 268
2024
Q2 		$6.75K Buy
+125
New +$7.23K 0.01% 436

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lynx Investment Advisory's CRSP Position: Q3 2024 in Review

Lynx Investment Advisory sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 125 shares — an estimated $6.75K sold.

Lynx Investment Advisory first reported a position in CRSP in Q2 2024 and held it in 1 quarter. The position peaked at $6.75K in Q2 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Lynx Investment Advisory reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Lynx Investment Advisory sold 125 CRISPR Therapeutics shares in Q3 2024, an estimated $6.75K.
  • Lynx Investment Advisory first reported a position in CRISPR Therapeutics in Q2 2024 and held it in 1 quarter.
  • Lynx Investment Advisory's CRISPR Therapeutics position peaked at $6.75K in Q2 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.